Angiogenesis and anti-angiogenesis in hepatocellular carcinoma
- 1 October 2006
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 32 (6) , 437-444
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- Thalidomide in the treatment of patients with hepatocellular carcinomaCancer, 2005
- Phase II study of thalidomide in patients with unresectable hepatocellular carcinomaCancer, 2004
- Concurrent delivery of GM‐CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumorsThe Journal of Gene Medicine, 2003
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- ANGPTL3 Stimulates Endothelial Cell Adhesion and Migration via Integrin αvβ3 and Induces Blood Vessel Formation in VivoJournal of Biological Chemistry, 2002
- The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapiesThe Journal of Pathology, 2002
- Complete Remission of Metastatic Cervical Cancer with the Angiogenesis Inhibitor TNP-470New England Journal of Medicine, 1998
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth FactorScience, 1992
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971